Download PDF
Neuropediatrics 2003; 34(3): 120-126
DOI: 10.1055/s-2003-41274
Original Article

Georg Thieme Verlag Stuttgart · New York

Glatiramer Acetate Treatment in Patients with Childhood and Juvenile Onset Multiple Sclerosis

B. Kornek[*] 1 , G. Bernert[*] 2 , C. Balassy 3 , J. Geldner 1 , D. Prayer 3 , M. Feucht 1
  • 1Department of Neuropsychiatry of Childhood and Adolescence, University of Vienna, Vienna, Austria
  • 2Department of Paediatrics, Division of Neuropediatrics, University of Vienna, Vienna, Austria
  • 3Department of Radiology, Division of Neuroradiology, University of Vienna, Vienna, Austria
Further Information

Publication History

Received: June 7, 2002

Accepted after Revision: March 9, 2003

Publication Date:
11 August 2003 (online)

    Permissions and Reprints

Abstract

Background

Recent data indicate that in multiple sclerosis disease onset before the age of 16 is more common than previously assumed. However, current therapeutic options are limited to the treatment of acute attacks in these patients. Glatiramer acetate has been successfully applied in adults with relapsing-remitting multiple sclerosis, but there are no data available about the use of glatiramer acetate in childhood and juvenile onset multiple sclerosis.

Methods

Seven patients with relapsing-remitting multiple sclerosis and disease onset between 9 and 16 years of age were treated with daily subcutaneous injection of 20 mg glatiramer acetate (Copaxone). Patients were followed for 24 months. Treatment was initiated in all patients before the age of 18.

Results

The use of glatiramer acetate in our cohort of early onset multiple sclerosis patients was safe and well tolerated. Two out of seven patients remained relapse-free during the two year period. Clinical disability as measured by the EDSS remained stable in three out of seven patients.

Conclusion

Due to the small number of patients the efficacy of the treatment has to be interpreted with caution. However, there might be a more pronounced treatment benefit in patients with low disability at treatment initiation and early treatment onset.

Key words

Multiple sclerosis - childhood-onset - glatiramer acetate

References

  • 1 Adams A B, Tyor W R, Holden K R. Interferon beta-1 b and childhood multiple sclerosis.  Pediatr Neurol. 1999;  21 481-483
    CrossrefPubMedGoogle Scholar
  • 2 Balassy C, Bernert G, Wöber-Bingöl C, Csapo B, Kornek B, Szeles J. et al . Long-term MRI observation of childhood-onset multiple sclerosis.  Neuropediatrics. 2001;  32 28-37
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D, University of British Columbia Clinic Neurologists M S. Early onset multiple sclerosis: a longitudinal study.  Neurology. 2002;  59 1006-1010
    CrossrefPubMedGoogle Scholar
  • 4 Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging with lesion pathology.  Ann Neurol. 1997;  42 783-793
    CrossrefPubMedGoogle Scholar
  • 5 Cole G F, Stuart C A. A long-term perspective on childhood multiple sclerosis.  Dev Med Child Neurol. 1995;  37 661-666
    PubMedGoogle Scholar
  • 6 Comi G, Filippi M, Wolinsky J S. and the European/Canadian Glatiramer Acetate Study Group . European/Canadian multicenter, double-blind, randomised, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis.  Ann Neurol. 2001;  49 290-297
    CrossrefPubMedGoogle Scholar
  • 7 Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O. et al . Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.  Lancet. 2001;  357 1576-1582
    CrossrefPubMedGoogle Scholar
  • 8 Dale R C, de Sousa C, Chong W K, Cox T CS, Harding B, Neville B GR. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children.  Brain. 2000;  123 2407-2422
    CrossrefPubMedGoogle Scholar
  • 9 Duquette P, Murray T J, Pleines J. Multiple sclerosis in childhood: clinical profile in 125 patients.  J Pediatr. 1987;  111 359-363
    CrossrefPubMedGoogle Scholar
  • 10 Ebers G. The natural history of multiple sclerosis. Compston A, Ebers G, Lassmann H, McDonalds I, Matthews B, Weherle H McAlpines' Multiple Sclerosis. 3rd ed. London; Churchill Livingstone 1998: 191-221
    Google Scholar
  • 11 Filippi M, Rovaris M, Rocca M A, Sormani M P, Wolinsky J S, Comi G. and the European Canadian Glatiramer Acetate Study Group . Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”.  Neurology. 2001;  57 731-733
    PubMedGoogle Scholar
  • 12 Filippi M, Grossman R I. MRI techniques to monitor MS evolution: The present and the future.  Neurology. 2002;  58 1147-1153
    PubMedGoogle Scholar
  • 13 Ghezzi A, Deplano V, Faroni J, Grasso M G, Liguori M, Marrosu G. et al . Multiple sclerosis in childhood: clinical features of 149 cases.  Mult Scler. 1997;  3 43-46
    CrossrefPubMedGoogle Scholar
  • 14 Hanefeld F A. Characteristics of childhood multiple sclerosis.  Int MSJ. 1994;  1 90-97
    PubMedGoogle Scholar
  • 15 Jacobs L D, Beck R W, Simon J H, Kinkel R P, Brownscheidle C M, Murray T J. et al . Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.  N Engl J Med. 2000;  343 898-904
    CrossrefPubMedGoogle Scholar
  • 16 Johnson K P, Brooks B R, Cohen J A, Ford C C, Goldstein J, Lisak R P. et al . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial.  Neurology. 1995;  45 1268-1276
    CrossrefPubMedGoogle Scholar
  • 17 Johnson K P, Brooks B R, Cohen J A, Ford C C, Goldstein J, Lisak R P. et al . Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability.  Neurology. 1998;  50 701-708
    CrossrefPubMedGoogle Scholar
  • 18 Johnson K P, Brooks B R, Ford C C, Goodman A, Guarnaccia J, Lisak R P. and the Copolymer Multiple Sclerosis Study Group . Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years.  Mult Scler. 2000;  6 255-266
    CrossrefPubMedGoogle Scholar
  • 19 Kurtzke J F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).  Neurology. 1983;  33 1444-1452
    CrossrefPubMedGoogle Scholar
  • 20 McDonald W I, Compston A, Edan G, Goodkin D, Hartung H P, Lublin F D. et al . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.  Ann Neurol. 2001;  50 121-127
    CrossrefPubMedGoogle Scholar
  • 21 Mikaeloff Y, Moreau T, Debouverie M, Pelletier J, Lebrun C, Gout O. et al . Interferon-β treatment in patients with childhood-onset multiple sclerosis.  J Pediatr. 2001;  139 443-446
    CrossrefPubMedGoogle Scholar
  • 22 Pohl D, Hanefeld F. Multiple Sklerose bei Kindern und Jugendlichen.  Akt Neurol. 2001;  28 8-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Rosati G. The prevalence of multiple sclerosis in the world: an update.  Neurol Sci. 2001;  22 117-139
    CrossrefPubMedGoogle Scholar
  • 24 Simone I L, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F. et al . Course and prognosis in early-onset MS: comparison with adult-onset forms.  Neurology. 2002;  59 1922-1928
    CrossrefPubMedGoogle Scholar
  • 25 Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: clinical and paraclinical features.  Acta Neurol Scand. 1992;  86 280-284
    PubMedGoogle Scholar
  • 26 Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system.  Cell. 1996;  85 299-302
    CrossrefPubMedGoogle Scholar
  • 27 van Walderveen M AA, Kamphorst W, Scheltens P, van Waesberghe J H, Ravid R, Valk J. et al . Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.  Neurology. 1998;  50 1282-1288
    PubMedGoogle Scholar
  • 28 Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J. et al . Interferon beta-1 a in children with multiple sclerosis is well tolerated.  Neuropediatrics. 2001;  32 211-213
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Weinshenker B G. Natural history of multiple sclerosis.  Ann Neurol. 1994;  36 (Suppl) S6-S11
    CrossrefPubMedGoogle Scholar
  • 30 Wolinsky J S, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G. The European/Canadian Glatiramer Acetate Study Group . Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained.  Neurology. 2002;  59 1284-1286
    PubMedGoogle Scholar
  • 31 Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis (review).  Drug Safety. 2001;  24 979-990
    PubMedGoogle Scholar

1 The authors contributed equally to the content of the paper

M. D. Barbara Kornek

Department of Neuropsychiatry of Childhood and Adolescence
University of Vienna

Währinger Gürtel 18 - 20

1090 Vienna

Austria

Email: barbara.kornek@univie.ac.at

      >